Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome

Autor: Marija Sarić, Duško Mirković, Ljudmila Stojanovich, Mirjana Bećarević, Svetlana Ignjatović, Violeta Dopsaj
Rok vydání: 2018
Předmět:
Adult
medicine.medical_specialty
Abortion
Habitual
Cardiolipins
030204 cardiovascular system & hematology
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Rheumatology
immune system diseases
Antiphospholipid syndrome
Pregnancy
Internal medicine
Anti-annexin A5 antibodies
medicine
Beta 2-Glycoprotein I
Humans
Annexin A5
25-hydroxy-cholecalciferol
Calcifediol
Cholecalciferol
Retrospective Studies
030203 arthritis & rheumatology
Lupus anticoagulant
biology
business.industry
Antiphospholipid antibodies
Thrombosis
General Medicine
Middle Aged
medicine.disease
Antiphospholipid Syndrome
3. Good health
Immunoglobulin M
beta 2-Glycoprotein I
Antibodies
Anticardiolipin
Immunoglobulin G
Lupus Coagulation Inhibitor
biology.protein
Antibodies
Antiphospholipid
Female
Antibody
business
Vitamin D3
Zdroj: Clinical Rheumatology
ISSN: 1434-9949
Popis: Vascular antiphospholipid syndrome (VAPS) and obstetric (OAPS) are different entities because some patients only develop thrombosis (without recurrent pregnancy losses) and vice versa. Only two articles have reported that low 25-hydroxy-cholecalciferol (vitamin D3, VD3) levels were not correlated with the presence of conventional antiphospholipid antibodies (aPL Abs: anticardiolipin (aCL), anti-beta2glycoprotein I (aβ2gpI), and lupus anticoagulant (LA)), but no article analyzed the association of VD3 and anti-annexin A5 (aanxA5) Abs. The aim of our study was to investigate the association between VD3, multiple positivity of conventional aPL and aanxA5 Abs levels only in female OAPS vs. VAPS. Our study included 62 consecutive female PAPS patients. Concentrations of Abs were measured by ELISA, while VD3 levels were determined by immunochemiluminescence. Only 10/62 (16.13%) had sufficient (≥ 30 ng/ml) VD3 levels, while 48/62 (77.42%) and 4/62 (6.45%) had insufficiency and VD3 deficiency, respectively. Statistically significant VD3 deficiency was noticed in VAPS (vs. OAPS, P = 0.013). A negative correlation between VD3 levels and the age of patients was noticed (r = - 0.493, P = 0.032) only in VAPS subgroup. Multiple positivity of aPL and aanxA5 Abs was not associated with VD3 deficiency. Newly emerging aPL Abs, such as aanxA5 Abs, or their combinations with classical aPL Abs are not associated with VD3 deficiency in neither OAPS nor VAPS patients. Due to its immunomodulatory roles in B-Ly homeostasis, supplementation with VD3 should be considered in APS, at least in subgroup with severe form of the disease, i.e., VAPS.
Databáze: OpenAIRE
Externí odkaz: